The FDA and Aging: Why We Need to Classify Aging as a Disease

The idea of classifying aging as a disease might seem counter-intuitive at first glance. After all, aging is a universal human experience, not typically viewed through the same lens as cancer or diabetes. However, a growing number of scientists, clinicians, and policymakers argue that formally recognizing aging as a disease by regulatory bodies like the U.S. Food and Drug Administration (FDA) is a crucial step toward developing effective interventions to extend healthy human lifespan. This shift in perspective could unlock new avenues for research, drug development, and ultimately, improve public health.

The Scientific Fight Over Whether Aging Is a Disease

The debate over whether aging constitutes a disease is not new, but it has intensified with advancements in geroscience. Traditionally, aging has been considered a natural, inevitable process. Diseases like heart disease, Alzheimer’s, and type 2 diabetes were seen as consequences of aging, rather than aging itself being the underlying condition. This distinction has profound implications for how we approach medical research and treatment.

Proponents of classifying aging as a disease point to its mechanistic underpinnings. We now understand that aging is not a passive decline but an active biological process driven by a set of fundamental mechanisms, often referred to as the “hallmarks of aging.” These include genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, deregulated nutrient sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, and altered intercellular communication. Each of these hallmarks can be targeted by specific interventions.

If aging is a process that can be mechanistically understood and modulated, then its negative outcomes—frailty, cognitive decline, increased susceptibility to chronic diseases—can be viewed as symptoms of this underlying condition. This perspective shifts the focus from treating individual age-related diseases in isolation to tackling the root cause: aging itself. For instance, instead of treating heart disease, then diabetes, then arthritis, a therapy targeting cellular senescence, a hallmark of aging, might simultaneously mitigate the risk or severity of all three conditions.

Opponents often raise concerns about medicalizing a natural process, fearing that it could lead to unnecessary interventions or a societal obsession with eternal youth. There are also semantic arguments: if everything that happens to us as we get older is a disease, does the term lose its meaning? However, proponents counter that the goal is not to stop aging entirely, but to extend “healthspan”—the period of life spent in good health, free from chronic disease and disability. The aim is to make the later years of life more vibrant and productive, not to prevent death.

It Is Time to Classify Biological Aging as a Disease

From a biological standpoint, the argument for classifying aging as a disease becomes clearer. Diseases are often defined by their pathological processes, identifiable symptoms, and detrimental effects on an organism’s function. Aging fits this description. As we age, our bodies accumulate damage at the cellular and molecular level, leading to a progressive decline in physiological integrity and an increased risk of morbidity and mortality.

Consider the parallels with other recognized diseases. Osteoporosis, for example, is characterized by bone density loss and increased fracture risk. While more common in older individuals, it’s not simply “normal aging” of the bones; it’s a pathological condition that can be diagnosed and treated. Similarly, sarcopenia, the age-related loss of muscle mass and strength, impairs mobility and quality of life, and is increasingly recognized as a treatable condition rather than an unavoidable consequence of getting older.

The World Health Organization (WHO) has already taken steps in this direction by including “Old age” (code MG2A) in its International Classification of Diseases (ICD-11) under “Symptoms, signs or clinical findings, not elsewhere classified.” While this is not a full classification of aging as a disease, it acknowledges that “aging-related” changes can have clinically significant impacts and require attention. This move by a global health authority provides a precedent and a framework for national regulatory bodies like the FDA to consider.

The practical implications of this classification are significant. If aging is a disease, then therapies designed to slow, halt, or reverse its biological mechanisms could be developed and approved. This would open the door for clinical trials that measure improvements in aging biomarkers or a reduction in multiple age-related conditions as primary endpoints, rather than focusing on a single disease.

Classifying Aging as a Disease Could Speed FDA Drug Approval

One of the most compelling arguments for the FDA to classify aging as a disease is the potential to accelerate the development and approval of longevity-promoting drugs. Currently, drug developers face a significant hurdle: the FDA does not recognize aging as a “treatable condition.” This means that a drug designed to target the fundamental processes of aging cannot be approved solely for “anti-aging” purposes. Instead, it must be approved for a specific age-related disease, such as type 2 diabetes, heart failure, or Alzheimer’s disease.

This regulatory framework creates several challenges:

• Narrow Indications: A drug that broadly impacts aging mechanisms might show modest benefits across many age-related diseases but not a dramatic effect on any single one. This makes it difficult to meet the stringent efficacy requirements for a specific disease indication.
• Complex Clinical Trials: To gain approval, drug developers must undertake large, expensive, and lengthy clinical trials for each individual age-related disease the drug might target. This significantly increases the cost and time to bring new therapies to market.
• “Orphan Drug” Dilemma: Many age-related conditions, while prevalent, are not considered “orphan diseases” (rare diseases affecting fewer than 200,000 people in the US), which receive special incentives for drug development. However, the underlying mechanisms of aging that contribute to these conditions are often neglected because there’s no direct pathway to approve therapies for them.

Consider the Targeting Aging with Metformin (TAME) trial, a proposed clinical study that aims to test whether metformin, an existing diabetes drug, can delay the onset of multiple age-related diseases. The TAME trial faces significant regulatory hurdles precisely because it seeks to address aging as a whole, rather than a single disease. If the FDA were to classify aging as a disease, trials like TAME could be designed with aging-specific endpoints, such as:

• Composite endpoints: Measuring the incidence of multiple age-related diseases (e.g., cardiovascular disease, cancer, cognitive decline, frailty) as a single outcome.
• Biomarkers of aging: Utilizing validated biological markers that reflect the rate of aging, such as epigenetic clocks, inflammatory markers, or cellular senescence burden.

Such a shift would streamline the approval process, reduce development costs, and incentivize pharmaceutical companies to invest more heavily in geroscience research. It would create a clear regulatory pathway for drugs that target the root causes of age-related decline, rather than just managing individual symptoms.

WHO and FDA Debate Over Classifying Aging As A Disease

The debate surrounding the classification of aging is not confined to scientific circles; it extends to major global and national health organizations. As mentioned, the WHO’s inclusion of “Old age” in ICD-11 signals a growing recognition that aging-related processes warrant clinical attention. This move, while not a full disease classification, represents a significant conceptual shift.

The FDA, however, operates under a different mandate and set of regulations. Its primary role is to ensure the safety and efficacy of drugs and medical devices for specific diseases or conditions. Without a clear definition of aging as a disease, the FDA cannot approve drugs for “anti-aging” or “longevity” per se. This creates a disconnect between the scientific understanding of aging as a modifiable biological process and the regulatory framework for medical interventions.

The ongoing discussions between groups advocating for aging classification and regulatory bodies often revolve around:

• Defining “disease”: What constitutes a disease? Is it a deviation from normal physiological function? If so, aging certainly fits, as it involves a progressive decline in organ system function.
• Measurable endpoints: How would one measure the efficacy of an “anti-aging” drug? This is where the development of robust aging biomarkers becomes critical. The FDA requires objective, measurable outcomes for drug approval.
• Public perception and ethical concerns: Would classifying aging as a disease lead to unnecessary medicalization, exacerbate health inequalities, or create unrealistic expectations of immortality? These are valid concerns that need careful consideration.

Despite the complexities, there is a growing consensus among longevity researchers that the FDA’s current stance is a major impediment to progress. The agency’s conservative approach, while understandable given its responsibility, inadvertently stifles innovation in a field with immense potential to improve human health.

FDA Doesn’t Classify Aging As a Disease, No Regulatory Pathway

The current reality is that the FDA does not classify aging as a disease. This fundamental position dictates the regulatory landscape for any drug or therapy aiming to address the aging process. Without this classification, there is no direct regulatory pathway for a drug whose sole purpose is to slow down or reverse aging.

This means that any company developing a potential “longevity drug” must identify a specific age-related disease that the drug can treat or prevent. For example, a drug that targets cellular senescence might be tested for its ability to prevent chronic obstructive pulmonary disease (COPD) or osteoarthritis, even if its broader effect is to improve overall healthspan. This approach forces developers to pigeonhole their innovative therapies into existing disease categories, often obscuring their true potential.

The lack of a direct regulatory pathway has several drawbacks:

• Limited Funding and Investment: Pharmaceutical companies are less likely to invest billions in drug development if the regulatory path to market is unclear or exceptionally arduous. The current system creates a high-risk, uncertain environment for geroscience-focused ventures.
• Delayed Innovation: Promising compounds that show broad anti-aging effects might languish in preclinical stages or be abandoned due to the prohibitive cost and complexity of navigating multiple disease-specific trials.
• Fragmented Research: The focus remains on single diseases, even when the underlying mechanisms are shared across multiple age-related conditions. This leads to a fragmented approach to research and treatment development.

For instance, consider a drug that could restore mitochondrial function, a key hallmark of aging. Such a drug might simultaneously improve energy levels, reduce inflammation, and enhance cognitive function. Under current FDA regulations, a developer would likely need to choose one specific indication, say, a rare mitochondrial disorder, or try to prove efficacy for a common condition like heart failure. This ignores the drug’s broader, systemic benefits related to aging.

The situation calls for a re-evaluation of the FDA’s stance, aligning regulatory policy with the evolving scientific understanding of aging.

Classifying Aging as a Disease in the Context of ICD-11

The International Classification of Diseases (ICD) is a global standard for health information, maintained by the World Health Organization (WHO). Its primary purpose is to classify diseases, signs and symptoms, abnormal findings, complaints, social circumstances, and external causes of injury or diseases. The latest version, ICD-11, includes a new code, MG2A, for “Old age.”

While “Old age” is not explicitly labeled as a “disease” in the traditional sense within ICD-11, its inclusion under “Symptoms, signs or clinical findings, not elsewhere classified” is a significant step. Here’s why:

• Official Recognition: It provides an official, internationally recognized code for clinicians and researchers to document and track health issues specifically attributable to aging.
• Research and Data Collection: It enables better data collection on the impact of aging on health, facilitating epidemiological studies and resource allocation.
• Precedent for Regulatory Bodies: It sets a precedent for national regulatory agencies, like the FDA, to consider how they classify and address aging. If the WHO recognizes “Old age” as a condition that can be clinically managed, it strengthens the argument for the FDA to recognize aging as a treatable condition.

Comparison: FDA vs. ICD-11 Approach to Aging

The ICD-11 classification, while not directly impacting FDA drug approval, provides a powerful conceptual tool. It allows healthcare providers to diagnose and track “Old age” as a contributing factor to various health issues, paving the way for a more integrated approach to geriatric care and, eventually, preventative geroscience. For the FDA, it presents an opportunity to align its regulatory framework with a broader, globally recognized understanding of aging’s clinical relevance.

Conclusion

The debate around whether the FDA should classify aging as a disease is more than a semantic argument; it’s a critical discussion with profound implications for public health, scientific research, and drug development. The current regulatory framework, which does not recognize aging as a treatable condition, creates significant hurdles for bringing innovative longevity-promoting therapies to market.

By formally classifying aging as a disease, the FDA could:

• Unlock new research avenues: Incentivize pharmaceutical companies and academic institutions to invest in geroscience.
• Streamline drug approval: Create a clear regulatory pathway for therapies that target the fundamental mechanisms of aging, potentially allowing for novel clinical trial designs with composite aging endpoints or validated biomarkers.
• Shift treatment paradigms: Move from a reactive approach of treating individual age-related diseases to a proactive strategy of preventing or delaying the onset of multiple chronic conditions simultaneously.
• Improve healthspan: Ultimately, the goal is not just to extend life, but to extend the period of healthy, active living, reducing the burden of age-related disease and disability on individuals and healthcare systems.

While concerns about medicalization and ethical considerations are valid and require careful navigation, the scientific understanding of aging has advanced to a point where it can no longer be viewed as an unmodifiable, natural process. Recognizing aging as a disease is a necessary step to harness this scientific progress and translate it into tangible health benefits for an aging global population. The time has come for regulatory bodies to adapt to this evolving understanding and pave the way for a future where healthy aging is not just a hope, but a medical reality.